Eli Lilly And Company (LLY) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Eli Lilly And Company  (NYSE: LLY)


Eli Lilly And's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Eli Lilly And's ROI in the third quarter of 2026?
Eli Lilly And Company achieved a return on average invested assets (ROI) of 32 % in its third quarter of 2026, this is above LLY's average return on investment of 15.35%.
Eli Lilly And Companys investments during the 12 months ending in the third quarter of 2026 are valued at $86 billion

ROI decreased relative to the period ending Jun 30 2026, due to the decline in net income.

Within the Healthcare sector 12 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 130, from total ROI ranking in the second quarter of 2026 at 184.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 46.04 % 47.24 % 42.43 % 43.05 % 39.8 %
Y / Y Net Income Change TTM 49.79 % 93.56 % 210.55 % 283.64 % 1797.57 %
Investment (TTM) in Millions 101,076 94,542 75,857 73,278 71,076
Return On Investment (TTM) 32 % 33.95 % 36.13 % 31.62 % 31.2 %
LLY's Overall Ranking # 130 # 184 # 171 # 209 # 266
Seq. Investment Change TTM 9.53 % 12.47 % 7.18 % 10.61 % 10.43 %
Seq. Net Income Change TTM 3.25 % 5.68 % 22.46 % 12.1 % 33.42 %
Net Income (TTM) in Millions 27,580 26,711 25,277 20,640 18,412

LLY Company Profile >> Back to LLY Roi Comparisons >> See Annual LLY Return On Investment



Return On Investment LLY's Ranking
Within: No.
Industry # 9
Sector # 13
Overall # 130

Return On Investment Statistics
High Average Low
36.13 %
15.35 %
-10 %
(Mar 31 2026)   (Dec. 31, 2008)







Financial Statements
Eli Lilly And's III. Quarter Investments $ 101,076 Millions LLY's Balance sheet
Eli Lilly And's III. Quarter Income $ 6,451 Millions Quarterly LLY's Income Statement
LLY's Income by Division See LLY's Income by Division


LLY Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 73,278 48,240 34,564 30,653 32,195
Y / Y Investment Growth 51.9 % 39.56 % 12.76 % -4.79 % -0.12 %
Net Income in Millions 20,640 10,590 5,240 6,245 5,582
Y / Y Net Income Growth 94.9 % 102.08 % -16.08 % 11.88 % -9.88 %
Annual Return On Investment 28.17 % 21.95 % 15.16 % 20.37 % 17.34 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 28.17 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LLY's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LLY's Competitors
Subscribers only: Roi for Eli Lilly And's Suppliers
Subscribers only: Return On Investment for LLY's Customers

Other Ratios
LLY's Roa LLY's Inventory Turnover Ratio LLY's Growth Rates LLY's Dividend Statistics
LLY's Profitability Ratios LLY's Asset Turnover Ratio LLY's Dividend Growth
LLY's Roe LLY's Valuation Ratios LLY's Financial Strength Ratios LLY's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %

Date modified: 2026-10-30T13:15:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.